



**Department of Vermont Health Access  
Pharmacy Benefits Management Program  
DUR Board Meeting Agenda**

---

October 22, 2024: 5:00 – 8:30 p.m.

- **Executive Session** **5:00 - 6:00**
  - **Introductions and Approval of DUR Board Minutes** **6:00 - 6:05**  
(Public Comment Prior to Board Action)
  - **DVHA Pharmacy Administration Updates** **6:05 - 6:10**
  - **DVHA Chief Medical Officer Updates** **6:10 - 6:15**
  - **Proposed 2024 DURB Meeting Schedule** **6:15- 6:20**
  - **Follow-up Items from Previous Meetings** **6:20 - 6:20**
    - None at this time.
  - **RetroDUR/ProDUR** **6:20- 6:30**
    - None at this time
  - **Clinical Update: Drug Reviews** **6:30-6:30**  
(Public comment prior to Board action)
- Biosimilar Drug Reviews (criteria will be discussed with Cytokine Modulator class)**
- Full New Drug Reviews**  
(Any new drug reviews that also fall within the Therapeutic Class Review (TCR) will be discussed during the Therapeutic Class Review)
- None at this time.
- **New Managed Therapeutic Drug Classes** **6:30 - 6:30**  
(Public comment prior to Board action)
  - **Therapeutic Drug Classes – Periodic Review** **6:30 – 6:30**  
(Public comment prior to Board action)
    - None at this time
  - **Review of Newly Developed/Revised Criteria** **6:30 – 8:25**  
(Public comment prior to Board action)

(All changes will be effective January 1, 2025, unless otherwise noted)

- ADHD Agents Long-Acting Stimulants/Amphetamine Products
- ADHD Agents Non-stimulant
- Anticonvulsants

- Anti-Diabetic Agents
  - GLP1s
  - SGLT2
  - Insulins
- Antipsychotics
- Bronchodilators, Beta Agonists/COPD Agents
- Cardiovascular/MACE Reduction Agents
- Cytokine Modulators (Includes the following PDL classes):
  - Ankylosing Spondylitis Injectables
  - Inflammatory Bowel Disease Biologics
  - Hidradenitis Suppurativa
  - Psoriasis
  - Rheumatoid, Juvenile, & Psoriatic Arthritis Biologics
- Endometriosis/Uterine Fibroids Agents
- Gastrointestinal Agents: Bowel Prep/Laxatives
- Glucocorticoids, Inhaled
- Hemophilia A Treatments
- Hyperammonia Treatments
- Immunologic Therapies for Asthma
- Immunomodulators, Dermatologic
- Movement Disorder Drugs
- Multiple Sclerosis Agents
- Neurotoxins
- Ophthalmic Agents
- Pulmonary Arterial Hypertension Agents, Endothelin receptor antagonists
- Sickle Cell Agents
- Thyroid Hormone Agents
- Urinary Antispasmodics
- Vaginal Anti-infectives

- **General Announcements** **8:25 – 8:30**  
[FDA adds warning about rare occurrence of serious liver injury with use of Veozah \(fezolinetant\) for hot flashes due to menopause | FDA](#)  
  
[FDA is alerting patients and health care professionals about the voluntary withdrawal of Oxbryta from the market due to safety concerns | FDA](#)

- **Adjourn** **8:30**